Efficient in vitro gene therapy with PEG siRNA lipid nanocapsules for passive targeting strategy in melanoma

Biotechnology Journal

Volumn 9, Issue 11, 2014, Pages 1389-1401

  Resnier, Pauline ^a,b   Lequinio, Pierre ^a,b   Lautram, Nolwenn ^a,b   André, Emilie ^a,b   Gaillard, Cédric ^c   Bastiat, Guillaume ^a,b   Benoit, Jean Pierre ^a,b   Passirani, Catherine ^a  

^a Groupe cologie et Conservation   (France)

^b UNIVERSITÉ D'ANGERS   (France)

^c INRA   (France)

Author keywords

CH50 assay; Cryo TEM imaging; Gene therapy; SiRNA Lipid nanocapsules; Transfection

Indexed keywords

CELL CULTURE; CHEMOTHERAPY; CHROMIUM COMPOUNDS; DERMATOLOGY; LIPOSOMES; NANOCAPSULES; ONCOLOGY; PATHOLOGY;

COMPLEMENT ACTIVATIONS; CRYO-TEM; ENCAPSULATION YIELDS; INTRAVENOUS INJECTIONS; LIPID NANOCAPSULES; SMALL INTERFERING RNA (SIRNA); SYNTHETIC NANOPARTICLES; TRANSFECTION;

GENE THERAPY;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; LIPID NANOCAPSULE; LIPOPLEX; LIPOSOME; MACROGOL; NANOCAPSULE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; LIPID; MACROGOL DERIVATIVE;

ARTICLE; CELL DENSITY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VITRO STUDY; MELANOMA; MELANOMA CELL; MELANOMA CELL LINE; MORPHOLOGY; NANOENCAPSULATION; NANOMEDICINE; PHYSICAL CHEMISTRY; PROTEIN INTAKE; SURFACE TENSION; TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROSCOPY; ZETA POTENTIAL; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; METABOLISM; NANOTECHNOLOGY; PROCEDURES; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; GENE SILENCING; GENETIC THERAPY; HUMANS; LIPIDS; MELANOMA; NANOCAPSULES; NANOTECHNOLOGY; POLYETHYLENE GLYCOLS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84911480982     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201400162     Document Type: Article

References (43)

1. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A. et al., Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391, 806-811.
2. Yuan, X., Naguib, S., Wu, Z., Recent advances of siRNA delivery by nanoparticles. Expert Opin. Drug Deliv. 2011, 8, 521-536.
3. Lee, J. M., Yoon, T. J., Cho, Y. S., Recent Developments in Nanoparticle-Based siRNA Delivery for Cancer Therapy. Biomed Res Int. 2013, 2013, 782041.
4. Resnier, P., Montier, T., Mathieu, V., Benoit, J. P. et al., A review of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials 2013, 34, 6429-6443.
5. Ambardekar, V. V., Wakaskar, R. R., Sharma, B., Bowman, J. et al., The efficacy of nuclease-resistant Chol-siRNA in primary breast tumors following complexation with PLL-PEG(5K). Biomaterials 2013, 34, 4839-4848.
6. Ravina, M., Cubillo, E., Olmeda, D., Novoa-Carballal, R. et al., Hyaluronic acid/chitosan-g-poly(ethylene glycol) nanoparticles for gene therapy: an application for pDNA and siRNA delivery. Pharm. Res. 2010, 27, 2544-2555.
7. Hadinoto, K., Sundaresan, A., Cheow, W. S., Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review. Eur. J. Pharm. Biopharm. 2013, 85, 424-443.
8. Terp, M. C., Bauer, F., Sugimoto, Y., Yu, B. et al., Differential efficacy of DOTAP enantiomers for siRNA delivery in vitro. Int. J. Pharm. 2012, 430, 328-334.
9. Martino, S., di Girolamo, I., Tiribuzi, R., D'Angelo, F. et al., Efficient siRNA delivery by the cationic liposome DOTAP in human hematopoietic stem cells differentiating into dendritic cells. J. Biomed. Biotechnol. 2009, 2009, 410260.
10. Mochizuki, S., Kanegae, N., Nishina, K., Kamikawa, Y. et al., The role of the helper lipid dioleoylphosphatidylethanolamine (DOPE) for DNA transfection cooperating with a cationic lipid bearing ethylenediamine. Biochim Biophys Acta. 2013, 1828, 412-418.
11. Heurtault, B., Saulnier, P., Pech, B., Proust, J. E. et al., A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm. Res. 2002, 19, 875-880.
12. Morille, M., Montier, T., Legras, P., Carmoy, N. et al., Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. Biomaterials 2010, 31, 321-329.
13. Morille, M., Passirani, C., Dufort, S., Bastiat, G. et al., Tumor transfection after systemic injection of DNA lipid nanocapsules. Biomaterials 2011, 32, 2327-2333.
14. David, S., Montier, T., Carmoy, N., Resnier, P. et al., Treatment efficacy of DNA lipid nanocapsules and DNA multimodular systems after systemic administration in a human glioma model. J. Gene Med. 2012, 14, 769-775.
15. David, S., Carmoy, N., Resnier, P., Denis, C. et al., In vivo imaging of DNA lipid nanocapsules after systemic administration in a melanoma mouse model. Int. J. Pharm. 2012, 423, 108-115.
16. David, S., Resnier, P., Guillot, A., Pitard, B. et al., siRNA LNCs - a novel platform of lipid nanocapsules for systemic siRNA administration. Eur. J. Pharm. Biopharm. 2012, 81, 448-552.
17. Resnier, P., David, S., Lautram, N., Delcroix, G. J. et al., EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro. Int. J. Pharm. 2013, 454, 748-755.
18. Bastiat, G., Pritz, C. O., Roider, C., Fouchet, F. et al., A new tool to ensure the fluorescent dye labeling stability of nanocarriers: A real challenge for fluorescence imaging. J. Control Release. 2013, 170, 334-342.
19. Gaillard, C., Douliez, J.-P., Cryo-TEM and AFM for the characterization of vesicle-like nanoparticle dispersions and self-assembled supramolecular fatty-acid-based structures: a few examples. in: A. Meìndez-Vilas (Ed.) Current Microscopy Contributions to Advances in Science and Technology, Vol 5, Formatex Research Center, 2012, pp. 912-922.
20. Tonelli, G., Oumzil, K., Nallet, F., Gaillard, C. et al., Amino acid-nucleotide-lipids: effect of amino acid on the self-assembly properties. Langmuir. 2013, 29, 5547-5555.
21. Anton, N., Saulnier, P., Gaillard, C., Porcher, E. et al., Aqueous-core lipid nanocapsules for encapsulating fragile hydrophilic and/or lipophilic molecules. Langmuir 2009, 25, 11413-11429.
22. Hirsjarvi, S., Bastiat, G., Saulnier, P., Benoit, J. P., Evaluation of surface deformability of lipid nanocapsules by drop tensiometer technique, and its experimental assessment by dialysis and tangential flow filtration. Int. J. Pharm. 2012, 434, 460-467.
23. Vonarbourg, A., Passirani, C., Desigaux, L., Allard, E. et al., The encapsulation of DNA molecules within biomimetic lipid nanocapsules. Biomaterials 2009, 30, 3197-3204.
24. Nishimura, Y., Mieda, H., Ishii, J., Ogino, C. et al., Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes. J. Nanobiotechnol. 2013, 11, 19.
25. Wei, W., Lv, P. P., Chen, X. M., Yue, Z. G. et al., Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression. Biomaterials 2013, 34, 3912-3923.
26. Zhang, Y., Peng, L., Mumper, R. J., Huang, L., Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials 2013, 34, 8459-8468.
27. Alaaeldin, E., Abu Lila, A. S., Moriyoshi, N., Sarhan, H. A. et al., The Co-Delivery of Oxaliplatin Abrogates the Immunogenic Response to PEGylated siRNA-Lipoplex. Pharm. Res. 2013, 30, 2344-2354.
28. Pitaksuteepong, T., Davies, N. M., Tucker, I. G., Rades, T., Factors influencing the entrapment of hydrophilic compounds in nanocapsules prepared by interfacial polymerisation of water-in-oil microemulsions. Eur. J. Pharm. Biopharm. 2002, 53, 335-342.
29. Macdonald, R. C., Gorbonos, A., Momsen, M. M., Brockman, H. L., Surface properties of dioleoyl-sn-glycerol-3-ethylphosphocholine, a cationic phosphatidylcholine transfection agent, alone and in combination with lipids or DNA. Langmuir 2006, 22, 2770-2779.
30. de Martimprey, H., Bertrand, J. R., Malvy, C., Couvreur, P. et al., New core-shell nanoparticules for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma. Pharm. Res. 2010, 27, 498-509.
31. Palanca-Wessels, M. C., Convertine, A. J., Cutler-Strom, R., Booth, G. C. et al., Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells. Mol. Ther. 2011, 19, 1529-1537.
32. Kim, H. J., Oba, M., Pittella, F., Nomoto, T. et al., PEG-detachable cationic polyaspartamide derivatives bearing stearoyl moieties for systemic siRNA delivery toward subcutaneous BxPC3 pancreatic tumor. J. Drug Target. 2012, 20, 33-42.
33. Yan, J., Berezhnoy, N. V., Korolev, N., Su, C. J. et al., Structure and internal organization of overcharged cationic-lipid/peptide/DNA self-assembly complexes. Biochim Biophys Acta. 2012, 1818, 1794-1800.
34. Hsu, S. H., Yu, B., Wang, X., Lu, Y. et al., Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. Nanomedicine 2013, 9, 1169-1180.
35. Lasic, D. D., Liposomes in gene delivery. CRC Press. 1997, 67-113.
36. Mathieu, V., Pirker, C., Martin de Lassalle, E., Vernier, M. et al., The sodium pump alpha1 sub-unit: A disease progression-related target for metastatic melanoma treatment. J. Cell. Mol. Med. 2009, 13, 3960-3972.
37. Lefranc, F., Kiss, R., The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia 2008, 10, 198-206.
38. Karpova, L., Eva, A., Kirch, U., Boldyrev, A. et al., Sodium pump alpha1 and alpha3 subunit isoforms mediate distinct responses to ouabain and are both essential for survival of human neuroblastoma. FEBS J. 2010, 277, 1853-1860.
39. Vonarbourg, A., Saulnier, P., Passirani, C., Benoit, J. P., Electrokinetic properties of noncharged lipid nanocapsules: influence of the dipolar distribution at the interface. Electrophoresis 2005, 26, 2066-2075.
40. Sandiford, L., Phinikaridou, A., Protti, A., Meszaros, L. K. et al., Bisphosphonate-anchored PEGylation and radiolabeling of superparamagnetic iron oxide: Long-circulating nanoparticles for in vivo multimodal (T1 MRI-SPECT) imaging. ACS Nano. 2013, 7, 500-512.
41. Perry, J. L., Reuter, K. G., Kai, M. P., Herlihy, K. P. et al., PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett. 2012, 12, 5304-5310.
42. Maeda, H., The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41, 189-207.
43. Maeda, H., Wu, J., Sawa, T., Matsumura, Y. et al., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control Release. 2000, 65, 271-284.